American Green Inc (OTCMKTS:ERBB) and GREENHOUSE SOLUTIONS (OTCMKTS:GRSU) announced that the two companies will work together to formulate, market and distribute proprietary topical cannabidiol products. Greenhouse Solutions will provide American Green with two proprietary topical pain formulations, one for equine and one for the humans. These formulations will thereafter be incorporated, with the 99.5% pure Cannabidiol derived from hemp cultivated in the EU.

Read why analyst may see a swing in the momentum for ERBB.

The products

The human topical formulation will contain no scent. Unlike other pain-relieving formulations, it will not result in any cold or hot sensation. The equine topical formulation is a proven DMSO-based Cannabidiol infused topical. It is anticipated to have better pain relieving qualities. Both the topical products are non-addictive, non-narcotic, non-steroidal and non-toxic. They do not contain acetaminophen or aspirin.

Analyst identify potential hold signals in GRSU.

The distinctive feature

Stephen Shearin, the President of American Green Inc (OTCMKTS:ERBB), said the partnership with Greenhouse is just the beginning. Greenhouse has the science team that can use their unique ‘CBD isolate’ and create products capable of having an effective and safe impact on equine and human well-being. Also, it will contribute significantly to company’s revenues. The CBD products can be manufactured and sold in American Green’s ZaZZZ vending machines across the world. As of now, American Green only charges for the use of these machines. The new association will enable the company to take benefit from retail sales generated from the machines.

The market

As per the American Pain Society, the percentage of people suffering from chronic pain in the U.S. is around 35.5%. It accounts for almost $100 billion of costs annually in direct health-care expenditure. Lost work time is another disadvantage. When it comes to the horse industry, it has a direct economic effect on the United States of $39 billion per year. The statistics represent a huge potential market for topical CBD products. As of now, the available drugs are often associated with unfavorable side effects, poor tolerability and concerns over long-term safety.